Selective estrogen receptor degraders and uses thereof
The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
A is —CR A ═ or —N═, as valency permits;
W is —NH—, —O—, or —S—;
a is 1, 2, or 3;
n is 1, 2, 3, or 4;
each instance of R 1 is independently hydrogen, halogen, substituted or unsubstituted alkyl, —OR A , or —CN;
R 2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl;
R 3 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —OR A , or —N(R B ) 2 ;
R 4 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —OR A or —N(R B ) 2 ;
R 5 is fluorine or chlorine;
R 6 is chlorine;
R 7 is hydrogen, halogen, substituted or unsubstituted alkyl, —OR A or —N(R B ) 2 ;
R A is hydrogen or substituted or unsubstituted alkyl, or oxygen protecting group; and
R B is hydrogen or substituted or unsubstituted alkyl, nitrogen protecting group, or optionally two R B are taken together with the intervening atoms to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl.
2. A compound of the formula:
or
or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
4. A method of treating breast cancer, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition of claim 3 .
5. The method of claim 4 , wherein the breast cancer is ER+ breast cancer.
6. The compound of claim 1 , wherein the compound is of the formula (IA):
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is —CH═.
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein W is —NH—.
9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein a is 1.
10. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 1 is —OMe, —CF 3 , or —CN.
11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 1.
12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is methyl or —CF 3 .
13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is fluorine or methyl.
14. The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein R 4 is fluorine or methyl.
15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is —CH 2 F.
16. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
17. A method of treating breast cancer, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition of claim 16 .
18. The method of claim 17 , wherein the breast cancer is ER+ breast cancer.